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Introduction. Hypoglycemia is the rate-limiting factor that often prevents 
patients with diabetes from safely and effectively achieving their glycemic goals [1, 2]. 
Hypoglycemic events can have serious implications for patient health, psychological 
well being, and adherence to treatment regimens, can impact the health economics of 
the patient, their employer [4]. It is primarily associated with treatment with insulin 
and insulin secretagogues, equally common for both types of diabetes [3, 5, 8]. 
While severe hypoglycemic events are undoubtedly dangerous to patients, 
equally important are nonsevere hypoglycemic events, which are frequently and 
incorrectly dismissed as unimportant because they can be asymptomatic [6]. In fact, 
nonsevere hypoglycemic events are actually much more common than severe 
hypoglycemic events, yet, nonsevere ones may go unrecognized. Even if they are 
recognized, they may not be significant enough to be remembered by the patient and 
to be mentioned to the primary care physician and are therefore also significantly 
under-reported [6]. Recurrent episodes of untreated hypoglycemia can lead to 
hypoglycemia-associated autonomic failure, an impaired ability of the body to counter-
regulate subsequent and more serious events, which leads to unawareness of 
hypoglycemia [8]. Hypoglycemia also commonly goes undetected when it occurs 
during the night. Nocturnal hypoglycemia can lead to serious clinical consequences, 
including sudden death during sleep, thought to be a result of cardiac rate and rhythm 
disturbances in response to prolonged nocturnal hypoglycemia [6]. 
Considering that, the purpose of this study was to discuss the importance of all 
hypoglycemic events in the successful management of patients with diabetes, 
emphasizing data regarding the incidence of hypoglycemia in type 2 diabetes patients 
taking insulin and/or oral hypoglycemic agents to estimate the prevalence of 
hypoglycemia and try to prevent it from happening. 
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Materials and methodology. To accomplish this, 15 patients with diabetes 
mellitus type 2 (47% men and 53% women, mean age – 60,9±1,44 years), hospitalized 
to Chernivtsi Regional Endocrinological Center, participated in the study.  
The verification of the diagnosis and disease severity was based on the acting 
national and international regulating documents. All patients underwent standard 
general clinical and laboratory-instrumental examination. Glucose blood concentration 
was determined by glucose oxidase method before and 2 hours after meal (pre- and 
postprandial glycemia) to assess carbohydrate metabolism. Detection of glycated 
haemoglobin (HbA1C) was used as informative criterion of continuous glycemic 
control (by colorimetric method).  
In 40% of participating patients the duration of diabetes was less than 5 years, 
in 20% – 6-10 years, in 40% of patients had diabetes longer than 10 years. Among all 
examined patients 40% were treated by oral hypoglycemic agents, 60% were on 
combined hypoglycemic therapy. 
Except standard clinical patients’ examination findings and information from 
medical records, self-report 10-item Hypoglycemia questionnaire, provided by the 
Hypoglycemic Health Association of Australia, was used in order to reveal 
unrecognized hypoglycemic episodes and to identify the probability of hypoglycemic 
events in the examined patients [7]. Individual’s risk profile was calculated according 
to scoring scheme by the assessment of hypoglycemia signs as «rarely», 
«occasionally», and «usually», being assigned a certain number of points. If total score 
was less than 8 points, hypoglycemia was considered as «unlikely», between 8 to 15 
points – as «possible», in case of total score above 15 – as «present». Despite this 
questionnaire is easy to fill in, the researcher accompanied the patients while they 
completed the questionnaires to aid quality control during data collection. 
Results and discussion. The analysis of carbohydrate metabolism parameters 
evidenced a poor compensation of the disease in patients of the examined cohort.  
According to the obtained findings, the probability of hypoglycemia 
development was assessed as «possible» only in 20% of the enrolled patients; all of 
them were on combined hypoglycemic therapy. In the majority of cases (80%) the 
«present» hypoglycemia was defined in the patients treated by various types of 
hypoglycemic therapy. Our analysis demonstrated, that the gradient for risk according 
to the age and duration of diabetes as well as to the level of its compensation was 
noticeable. 
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Thus, the frequency of hypoglycemia in people with type 2 diabetes, mostly 
middle aged or elderly, is usually underestimated and much higher than documented. 
Impaired awareness of hypoglycemia, more prevalent in type 2 diabetes than is 
appreciated, is associated with increased risk of a variety of adverse clinical outcomes, 
including microvascular events (nephropathy, retinopathy, neuropathy), macrovascular 
events (heart failure, peripheral vascular disease, myocardial events, stroke), and death. 
Accompanied by such factors, as age, a past history of vascular disease, interactions 
with other drugs, alongside with treatment either by sulfonylureas or insulin, 
hypoglycemia poses particular problems and the mortality may be unrecognized. 
Though the risk of therapy-induced hypoglycemia is highest among patients 
treated with insulin, there are risks associated with other treatments. Sulfonylurea 
therapy, which increases insulin output from the pancreas, is one of the key 
contributors to hypoglycemia in patients with type 2 diabetes who are early in the 
progression of the disease. The risk of hypoglycemia with oral antidiabetes drugs is 
variable and, as with sulfonylureas, depends upon their respective pharmacokinetic and 
pharmacodynamic profiles. It is important to remember that if insulin or insulin 
secretagogues, such as a sulfonylurea, are added into the treatment regimen as the 
disease progresses, the risk of hypoglycemia will increase.  
The incidence of type 2 diabetes is projected to increase in coming years, while 
the average age of patients with type 2 diabetes is decreasing; therefore, the number of 
patients with advanced type 2 diabetes, for whom sulfonylureas and oral antidiabetes 
drugs will not provide sufficient glycemic control, and who will require the addition of 
insulin to their treatment regimen, is also likely to increase dramatically. Combined 
with increasingly tighter glycemic targets, this may contribute to an increasing 
prevalence of hypoglycemia in the future. 
Conclusion. A recent inquiry emphasised the benefits of using charts or scores 
for hypoglycaemia risk assessment in getting treatment decisions made alongside 
realistic estimates of patient susceptibility to hypoglycemia as the rate-limiting factor 
for the achievement of glycemic treatment goals. Such approach to the individual 
patient has daily practice implications, as it provides a useful tool for primary care 
physicians, who are responsible for guiding therapy to achieve euglycemic control in 
patients with diabetes. It helps to recognize asymptomatic hypoglycemia and to 
optimize management and outcomes in patients who are initially categorized as at 
hypoglycemia risk. 
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